All-Comers versus Enrichment Design Strategy in Phase II Trials
Open Access
- 1 April 2011
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (4) , 658-660
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Crizotinib — Latest Champion in the Cancer Wars?New England Journal of Medicine, 2010
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Randomized Phase II Trials: Time for a New Era in Clinical Trial DesignJournal of Thoracic Oncology, 2010
- Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical ResearchJournal of Clinical Oncology, 2010
- Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challengesStatistics in Medicine, 2010
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical ChallengesJournal of Clinical Oncology, 2009
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology & Therapeutics, 2009
- Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicineClinical Trials, 2008
- Evaluating the Efficiency of Targeted Designs for Randomized Clinical TrialsClinical Cancer Research, 2004